Vaccine Adjuvants Market 2030: How Particulate Adjuvants Lead the Charge
The global vaccine adjuvants marke t was valued at USD 3.66 billion in 2024 and is anticipated to reach USD 5.07 billion by 2030 , registering a compound annual growth rate (CAGR) of 5.69% from 2025 to 2030 . The market's expansion is primarily driven by the growing demand for effective vaccines to counter both emerging and re-emerging infectious diseases, along with the rising incidence of chronic illnesses such as cancer. The increasing awareness of adjuvants' critical role in enhancing the strength, duration, and scope of immune responses is accelerating their adoption across prophylactic and therapeutic vaccine development. Technological advances in immunology and molecular biology have paved the way for next-generation adjuvants, including saponin-based adjuvants and toll-like receptor (TLR) agonists , which target specific immune mechanisms. These innovations enhance vaccine safety and effectiveness while enabling lower antigen usage, thereby supporting scalability and...